Viking Therapeutics (VKTX) Panoramica del titolo
Viking Therapeutics, Inc. è una società biofarmaceutica in fase clinica che si concentra sullo sviluppo di nuove terapie per i disturbi metabolici ed endocrini. Maggiori dettagli
| Punteggio fiocco di neve | |
|---|---|
| Valutazione | 0/6 |
| Crescita futura | 0/6 |
| Prestazioni passate | 0/6 |
| Salute finanziaria | 6/6 |
| Dividendi | 0/6 |
VKTX Community Fair Values
Create NarrativeSee what 147 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Concorrenti di Viking Therapeutics, Inc.
Storia dei prezzi e prestazioni
| Prezzi storici delle azioni | |
|---|---|
| Prezzo attuale dell'azione | US$37.81 |
| Massimo di 52 settimane | US$43.15 |
| Minimo di 52 settimane | US$22.96 |
| Beta | 0.65 |
| Variazione di 1 mese | 27.61% |
| Variazione a 3 mesi | 6.48% |
| Variazione di 1 anno | 19.54% |
| Variazione a 3 anni | 148.42% |
| Variazione a 5 anni | 540.85% |
| Variazione dall'IPO | 321.99% |
Notizie e aggiornamenti recenti
Seeking Alpha • Jun 30
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Summary Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk’s oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs’ commercial potential and raising the value of VKTX’s oral program. VKTX’s injectable VK2735 faces intensified competition after Eli Lilly’s Retatrutide Phase III results, which establish a higher efficacy standard (>24%). I await VKTX’s upcoming oral maintenance study for clarity on tolerability and commercial positioning before reconsidering a Buy stance. Read the full article on Seeking AlphaArticolo di analisi • Jun 20
Viking Therapeutics (VKTX) Stock Could Be 67.2% Undervalued After Analysts Back VK2735
Executive change adds experience to Viking Therapeutics' clinical ambitions Viking Therapeutics (VKTX) recently drew fresh attention after analyst reports highlighted the potential of obesity drug candidate VK2735, and the company added further depth by appointing Hubert C. Chen, M.D., as chief medical officer. For investors watching Viking Therapeutics stock, Dr. Chen’s background across drug discovery, clinical development, and regulatory strategy adds another layer to the story around...Recent updates
Seeking Alpha • Jun 30
Viking Therapeutics: Updating Pipeline Potential As Oral GLP‑1s Accelerate
Summary Viking Therapeutics, Inc. maintains a Hold rating, reflecting a balanced risk-reward at its current ~$5B valuation amid sector momentum. Novo Nordisk’s oral Wegovy launch sets a new benchmark, highlighting peptide-based oral GLP-1 drugs’ commercial potential and raising the value of VKTX’s oral program. VKTX’s injectable VK2735 faces intensified competition after Eli Lilly’s Retatrutide Phase III results, which establish a higher efficacy standard (>24%). I await VKTX’s upcoming oral maintenance study for clarity on tolerability and commercial positioning before reconsidering a Buy stance. Read the full article on Seeking AlphaArticolo di analisi • Jun 20
Viking Therapeutics (VKTX) Stock Could Be 67.2% Undervalued After Analysts Back VK2735
Executive change adds experience to Viking Therapeutics' clinical ambitions Viking Therapeutics (VKTX) recently drew fresh attention after analyst reports highlighted the potential of obesity drug candidate VK2735, and the company added further depth by appointing Hubert C. Chen, M.D., as chief medical officer. For investors watching Viking Therapeutics stock, Dr. Chen’s background across drug discovery, clinical development, and regulatory strategy adds another layer to the story around...
Nuova narrativa • Mar 19
Obesity Pipeline And Phase III Milestones Will Transform This Cardiometabolic Pure Play
Catalysts About Viking Therapeutics Viking Therapeutics focuses on developing therapies for obesity and related cardiometabolic conditions, with VK2735 as its lead dual GLP-1 and GIP receptor agonist program in both injectable and oral forms. What are the underlying business or industry changes driving this perspective?
Nuova narrativa • Mar 05
Obesity Pipeline Expansion And Late Stage Trials Will Support Long Term Bullish Thesis
Catalysts About Viking Therapeutics Viking Therapeutics is a clinical stage biopharmaceutical company focused on therapies for obesity and related metabolic disorders. What are the underlying business or industry changes driving this perspective?Seeking Alpha • Apr 15
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
Summary 13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market. The global non-alcoholic steatohepatitis treatment market size is projected to reach $92.5 billion by 2034. Read the full article on Seeking AlphaSeeking Alpha • Feb 05
Viking Therapeutics: Why The Oral VK2735 Phase 2 Readout Could Send The Stock Soaring
Summary Oral VK2735 is strategically positioned to become a best-in-class oral GLP-1 therapy, with the Phase 2 trial data readout in H2 2025 serving as a critical catalyst. Phase 1 data for VK2735 represents the best efficacy and safety profile ever reported for an oral GLP-1 drug. The oral obesity market is projected to be the fastest-growing segment within the broader weight-loss market, driven by the superior convenience of oral formulations compared to injectable treatments. Similar read-outs, the option market and current valuation of VKTX of $3.64 Bn imply huge stock price upside to $52 upon positive trial data. Read the full article on Seeking AlphaArticolo di analisi • Dec 23
We're Interested To See How Viking Therapeutics (NASDAQ:VKTX) Uses Its Cash Hoard To Grow
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Viking Therapeutics...Seeking Alpha • Dec 19
Viking Therapeutics: Holiday Gift
Summary Viking Therapeutics has seen a significant drop, losing 50% in value since late October, despite positive news and promising GLP-1 drug developments. The biotech's oral GLP-1 candidate VK2735 showed impressive weight loss results and tolerability, with potential advantages over current weekly injectable treatments. Concerns about manufacturing costs and scalability exist, but Viking's strong pipeline and market potential in obesity make it a compelling investment. Analysts remain bullish, with the average price target at $110, reflecting a substantial upside potential of 187% from current levels. Read the full article on Seeking AlphaSeeking Alpha • Dec 05
Viking Stock Pops, Then Drops On Latest Obesity/MASH Data: Why I'm Still Bullish
Summary Viking Therapeutics is a strong contender in the GLP-1 obesity drug market - candidate VK2735 has the potential to challenge Eli Lilly's Zepbound and Novo Nordisk's Wegovy. The latest data from the oral and subcu versions of Viking's drug are encouraging, albeit pivotal studies must still be arranged and negotiated successfully. If approved, VK2735 will need to show it has a best-in-class profile in terms of either durability, dosing regimen, side effect profile, price or mode of administration. Despite manufacturing concerns, Viking's potential for blockbuster revenues and competitive differentiation makes it an attractive M&A target for Big Pharma. I'm not changing my buy rating on Viking as its GLP candidate looks likely to be the next to join commercial markets, and if M&A does happen, I suspect Viking would command a price >$10bn. Read the full article on Seeking AlphaSeeking Alpha • Nov 04
Viking Therapeutics: Too Much Excitement Around Oral VK2735, Even If It Met High Expectations
Summary Viking Therapeutics' oral VK2735 reported strong weight loss and good safety and tolerability in the phase 1 trial, with the 100mg dose achieving 8.2% absolute weight loss in four weeks. These results put Viking at the front of the oral obesity field, but with a major caveat of rapid treatment landscape evolution. The sell news reaction is understandable given high investor excitement ahead of the data update, and the fact there are no meaningful catalysts until at least Q4 2025. While the stock may consolidate in the near-term, the long-term outlook has improved for Viking after new oral VK2735 data. Read the full article on Seeking AlphaSeeking Alpha • Oct 28
Viking Therapeutics: Lots Of Positives
Summary Viking Therapeutics' VK2735 drug shows promising weight-loss results, driving a stock rally and positive analyst sentiment due to its potential in a $40 billion market. The company plans to escalate VK2735 dosages and start Phase 2 trials, with Phase 3 trials for the injectable version and VK2809 NASH drug also in the pipeline. The stock has a market cap below $9 billion while larger competitors have seen stock valuations soar by multiples of these levels indicating the opportunity for Viking Therapeutics. Read the full article on Seeking AlphaSeeking Alpha • Sep 25
Viking Therapeutics: Market Rightly Excited By GLP-1 Promise -- A Buy Ahead Of Data
Summary Viking Therapeutics, Inc. stock has surged nearly 1,500% since 2023, driven by the promising GLP-1/GIP receptor agonist VK-2735 for obesity. VK-2735's Phase 2 data showed weight loss comparable to Novo Nordisk's Wegovy and Eli Lilly's Zepbound, pitching it to one day compete in a >$150bn market. Viking's strong financial position, upcoming Phase 3 trials, and potential oral formulation of VK-2735 justify upgrading the stock to a “Buy.”. The company's secondary NASH candidate, VK2809, provides a hedge against risks, adding to Viking's investment appeal. It should be noted that VK2735 data is immature and there are many more tests to come — upcoming data from a Phase 1 study of oral VK2735 is a potentially significant catalyst for upside. Read the full article on Seeking AlphaArticolo di analisi • Sep 07
Companies Like Viking Therapeutics (NASDAQ:VKTX) Can Afford To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Seeking Alpha • Aug 30
Viking Therapeutics: GLP-1/GIP Receptor Agonist And Its Competitive Landscape
Summary Viking Therapeutics' VK2735, a dual GLP-1/GIP receptor agonist, shows promising results in Phase II trials for obesity treatment with potential for both subcutaneous and oral formulations. Despite competition from Eli Lilly and Novo Nordisk, VK2735's unique oral formulation could position Viking as a strong contender in the obesity drug market. VKTX's financial stability, with $942 million in cash and equivalents, supports its ongoing and future clinical trials, making it a viable long-term investment. I rate Viking Therapeutics as a "Buy" for high-risk tolerant investors, driven by VK2735's potential and additional upside from VK2809 and preclinical assets. Read the full article on Seeking AlphaSeeking Alpha • Jul 25
Viking Therapeutics: Better-Than-Expected Trial Timelines While Pipeline Expands
Summary Viking Therapeutics, Inc. provided a better-than-expected pipeline update when it reported second quarter earnings. Subcutaneous VK2735 will advance straight into a phase 3 trial, and this should speed up its potential market arrival by at least 18–24 months. Oral VK2735 has advanced to the 100mg cohort, with management making positive remarks about tolerability in the 60mg and 80mg dose cohorts. A novel amylin candidate was added to the pipeline with an IND submission expected in 2025. These updates strengthen both the standalone and M&A investment thesis on Viking Therapeutics. Read the full article on Seeking AlphaArticolo di analisi • Apr 26
We Think Viking Therapeutics (NASDAQ:VKTX) Can Easily Afford To Drive Business Growth
Just because a business does not make any money, does not mean that the stock will go down. By way of example, Viking...Seeking Alpha • Apr 02
Viking Therapeutics: Future Weight Loss Heavyweight?
Summary Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company’s value seems to be derived from its weight loss and NASH/MASH candidates. VK2735, the weight loss candidate, presents a potentially massively large opportunity, despite the crowded market. VK2809, the NASH/MASH candidate, now offers an attractive opportunity as a recently launched drug provides proof-of-concept for the space. Read the full article on Seeking AlphaArticolo di analisi • Jan 09
We're Hopeful That Viking Therapeutics (NASDAQ:VKTX) Will Use Its Cash Wisely
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Viking Therapeutics...Articolo di analisi • Sep 21
We're Not Very Worried About Viking Therapeutics' (NASDAQ:VKTX) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, Viking Therapeutics...Articolo di analisi • Jun 07
Viking Therapeutics (NASDAQ:VKTX) Is In A Good Position To Deliver On Growth Plans
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rendimenti per gli azionisti
| VKTX | US Biotechs | US Mercato | |
|---|---|---|---|
| 7D | -5.4% | -3.5% | 0.8% |
| 1Y | 19.5% | 32.8% | 20.5% |
Ritorno vs Industria: VKTX ha avuto una performance inferiore rispetto al US Biotechs che ha registrato un rendimento 32.8 % nell'ultimo anno.
Rendimento vs Mercato: VKTX ha eguagliato il mercato US che ha restituito 20.5 % nell'ultimo anno.
Volatilità dei prezzi
| VKTX volatility | |
|---|---|
| VKTX Average Weekly Movement | 7.8% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
Prezzo delle azioni stabile: VKTX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi rispetto al mercato US.
Volatilità nel tempo: La volatilità settimanale ( 8% ) di VKTX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda
| Fondato | I dipendenti | AMMINISTRATORE DELEGATO | Sito web |
|---|---|---|---|
| 2012 | 59 | Brian Lian | www.vikingtherapeutics.com |
Viking Therapeutics, Inc. è una società biofarmaceutica in fase clinica che si concentra sullo sviluppo di nuove terapie per i disturbi metabolici ed endocrini. Il suo candidato farmaco principale è VK2809, un agonista selettivo del recettore beta degli ormoni tiroidei (TRß), disponibile per via orale, che è in fase di sperimentazione clinica di Fase IIb per il trattamento di pazienti affetti da steatoepatite non alcolica confermata da biopsia e da NAFLD. L'azienda sviluppa VK5211, un modulatore selettivo non steroideo del recettore degli androgeni, disponibile per via orale, che è in fase II di sperimentazione clinica per il trattamento di pazienti che si stanno riprendendo da un intervento chirurgico non elettivo di frattura dell'anca; VK0612, che è in fase II di sperimentazione clinica per i disturbi metabolici e l'anemia; VK2735, un nuovo agonista doppio del peptide 1 glucagone-simile, che è in fase 1 di sperimentazione clinica per SAD/MAD, e VK0214, un agonista selettivo per tessuto e sottotipo recettoriale del TRß, disponibile per via orale, per l'adrenoleucodistrofia X-linked.
Viking Therapeutics, Inc. Riepilogo dei fondamenti
| VKTX statistiche fondamentali | |
|---|---|
| Capitalizzazione di mercato | US$4.41b |
| Utili (TTM) | -US$472.33m |
| Ricavi(TTM) | n/a |
0.0x
Rapporto P/S-9.3x
Rapporto P/EVKTX è sopravvalutato?
Vedi Fair Value e analisi di valutazioneUtili e ricavi
| VKTX Conto economico (TTM) | |
|---|---|
| Ricavi | US$0 |
| Costo del fatturato | US$0 |
| Profitto lordo | US$0 |
| Altre spese | US$472.34m |
| Utili | -US$472.33m |
Ultimi utili riportati
Mar 31, 2026
Prossima data di guadagno
n/a
| Utile per azione (EPS) | -4.07 |
| Margine lordo | 0.00% |
| Margine di profitto netto | 0.00% |
| Rapporto debito/patrimonio netto | 0% |
Come si è comportato VKTX nel lungo periodo?
Vedi performance storica e confrontoAnalisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/15 02:13 |
| Prezzo dell'azione a fine giornata | 2026/07/15 00:00 |
| Utili | 2026/03/31 |
| Utili annuali | 2025/12/31 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Viking Therapeutics, Inc. è coperta da 32 analisti. 17 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Matthew Luchini | BMO Capital Markets Equity Research |
| Mayank Mamtani | B. Riley Securities, Inc. |
| William Wood | B. Riley Securities, Inc. |